| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Postoperative Complications | 37 | 2024 | 2453 | 5.450 |
Why?
|
| Liver Neoplasms | 17 | 2025 | 765 | 4.770 |
Why?
|
| Hospitals | 22 | 2024 | 312 | 4.620 |
Why?
|
| Colorectal Neoplasms | 17 | 2025 | 1041 | 4.600 |
Why?
|
| Venous Thromboembolism | 13 | 2024 | 165 | 4.530 |
Why?
|
| Hepatic Artery | 10 | 2025 | 83 | 4.440 |
Why?
|
| Infusions, Intra-Arterial | 10 | 2025 | 39 | 3.960 |
Why?
|
| Pancreatic Neoplasms | 18 | 2025 | 696 | 3.590 |
Why?
|
| Colonic Neoplasms | 10 | 2024 | 581 | 3.530 |
Why?
|
| Surgical Procedures, Operative | 13 | 2024 | 210 | 3.380 |
Why?
|
| Adenocarcinoma | 19 | 2023 | 1191 | 3.290 |
Why?
|
| Patient Discharge | 13 | 2024 | 338 | 2.970 |
Why?
|
| Colectomy | 11 | 2022 | 179 | 2.760 |
Why?
|
| Neoplasms | 19 | 2023 | 3124 | 2.720 |
Why?
|
| Esophageal Neoplasms | 11 | 2024 | 338 | 2.420 |
Why?
|
| Quality Indicators, Health Care | 7 | 2021 | 152 | 2.370 |
Why?
|
| Digestive System Surgical Procedures | 7 | 2024 | 134 | 2.320 |
Why?
|
| Aftercare | 7 | 2023 | 88 | 2.310 |
Why?
|
| Appendiceal Neoplasms | 3 | 2021 | 31 | 2.030 |
Why?
|
| Humans | 158 | 2025 | 92340 | 2.020 |
Why?
|
| Quality Improvement | 18 | 2024 | 474 | 2.000 |
Why?
|
| United States | 48 | 2025 | 7348 | 1.910 |
Why?
|
| Cholangiocarcinoma | 4 | 2025 | 77 | 1.870 |
Why?
|
| Esophagectomy | 8 | 2021 | 91 | 1.850 |
Why?
|
| Retrospective Studies | 50 | 2024 | 9689 | 1.850 |
Why?
|
| Bile Duct Neoplasms | 4 | 2025 | 90 | 1.840 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2024 | 112 | 1.830 |
Why?
|
| Pancreatectomy | 8 | 2025 | 164 | 1.800 |
Why?
|
| Patient Readmission | 13 | 2024 | 391 | 1.710 |
Why?
|
| Aged | 69 | 2025 | 19951 | 1.650 |
Why?
|
| Neoplasm Staging | 24 | 2025 | 2035 | 1.640 |
Why?
|
| Stomach Neoplasms | 7 | 2025 | 296 | 1.550 |
Why?
|
| Lymph Node Excision | 6 | 2023 | 225 | 1.480 |
Why?
|
| Lymph Nodes | 9 | 2023 | 552 | 1.470 |
Why?
|
| Quality of Health Care | 10 | 2024 | 390 | 1.460 |
Why?
|
| Hepatectomy | 8 | 2024 | 174 | 1.450 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2021 | 48 | 1.430 |
Why?
|
| Medicare | 9 | 2023 | 440 | 1.430 |
Why?
|
| Surgical Oncology | 2 | 2022 | 28 | 1.420 |
Why?
|
| Healthcare Disparities | 6 | 2024 | 443 | 1.410 |
Why?
|
| General Surgery | 6 | 2021 | 238 | 1.390 |
Why?
|
| Middle Aged | 69 | 2025 | 27043 | 1.390 |
Why?
|
| Surgeons | 5 | 2021 | 263 | 1.350 |
Why?
|
| Male | 80 | 2025 | 43927 | 1.340 |
Why?
|
| Female | 82 | 2025 | 47893 | 1.300 |
Why?
|
| Colorectal Surgery | 3 | 2016 | 22 | 1.300 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 163 | 1.280 |
Why?
|
| Postoperative Care | 4 | 2016 | 238 | 1.280 |
Why?
|
| Risk Adjustment | 9 | 2016 | 40 | 1.270 |
Why?
|
| Length of Stay | 9 | 2024 | 790 | 1.190 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2023 | 485 | 1.170 |
Why?
|
| Rectal Neoplasms | 4 | 2020 | 132 | 1.100 |
Why?
|
| Quality Assurance, Health Care | 5 | 2022 | 226 | 1.080 |
Why?
|
| Medical Oncology | 5 | 2025 | 393 | 1.060 |
Why?
|
| Risk Assessment | 14 | 2024 | 2368 | 1.030 |
Why?
|
| Laparoscopy | 8 | 2024 | 767 | 1.000 |
Why?
|
| Chemoprevention | 3 | 2023 | 93 | 0.970 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 1398 | 0.960 |
Why?
|
| Neoadjuvant Therapy | 8 | 2022 | 400 | 0.950 |
Why?
|
| Risk Factors | 21 | 2025 | 5706 | 0.940 |
Why?
|
| Surgical Wound Infection | 6 | 2022 | 224 | 0.940 |
Why?
|
| Nomograms | 1 | 2025 | 33 | 0.920 |
Why?
|
| Registries | 7 | 2020 | 903 | 0.920 |
Why?
|
| Quality Control | 2 | 2022 | 117 | 0.910 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2024 | 275 | 0.900 |
Why?
|
| Infusion Pumps, Implantable | 3 | 2023 | 25 | 0.880 |
Why?
|
| Treatment Outcome | 22 | 2024 | 8730 | 0.870 |
Why?
|
| Follow-Up Studies | 22 | 2024 | 3776 | 0.870 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2024 | 34 | 0.850 |
Why?
|
| Liver Failure | 2 | 2024 | 69 | 0.850 |
Why?
|
| Feasibility Studies | 4 | 2023 | 800 | 0.840 |
Why?
|
| Patient Compliance | 2 | 2016 | 236 | 0.840 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 436 | 0.820 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 886 | 0.820 |
Why?
|
| Hospitals, High-Volume | 4 | 2024 | 39 | 0.790 |
Why?
|
| Medicaid | 3 | 2023 | 248 | 0.780 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2022 | 17 | 0.780 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 1072 | 0.760 |
Why?
|
| Health Status Disparities | 2 | 2023 | 201 | 0.760 |
Why?
|
| Nursing Staff, Hospital | 1 | 2022 | 42 | 0.740 |
Why?
|
| Drainage | 2 | 2020 | 168 | 0.740 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2022 | 82 | 0.730 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2022 | 98 | 0.730 |
Why?
|
| Research Report | 1 | 2021 | 44 | 0.710 |
Why?
|
| Health Literacy | 1 | 2022 | 73 | 0.710 |
Why?
|
| Survival Rate | 13 | 2025 | 1926 | 0.710 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2020 | 609 | 0.710 |
Why?
|
| Models, Statistical | 4 | 2014 | 578 | 0.700 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 2556 | 0.680 |
Why?
|
| Prospective Payment System | 1 | 2020 | 8 | 0.670 |
Why?
|
| Preoperative Care | 4 | 2019 | 405 | 0.670 |
Why?
|
| Logistic Models | 13 | 2020 | 1239 | 0.660 |
Why?
|
| Occupational Exposure | 1 | 2021 | 88 | 0.660 |
Why?
|
| Organizational Objectives | 1 | 2020 | 24 | 0.660 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 52 | 0.650 |
Why?
|
| Efficiency | 1 | 2020 | 39 | 0.650 |
Why?
|
| Databases, Factual | 12 | 2024 | 955 | 0.640 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 55 | 0.640 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 176 | 0.640 |
Why?
|
| Professional Competence | 1 | 2020 | 69 | 0.630 |
Why?
|
| Product Recalls and Withdrawals | 1 | 2019 | 2 | 0.630 |
Why?
|
| Cholestasis | 1 | 2019 | 43 | 0.620 |
Why?
|
| Statistics as Topic | 1 | 2020 | 234 | 0.620 |
Why?
|
| Anesthesia | 1 | 2021 | 167 | 0.620 |
Why?
|
| Adult | 35 | 2024 | 27538 | 0.620 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 85 | 0.600 |
Why?
|
| Hyperthermia, Induced | 1 | 2019 | 74 | 0.600 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 606 | 0.590 |
Why?
|
| Lung Neoplasms | 5 | 2024 | 2396 | 0.570 |
Why?
|
| Robotic Surgical Procedures | 2 | 2024 | 342 | 0.570 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2014 | 72 | 0.540 |
Why?
|
| Abdominal Neoplasms | 2 | 2020 | 40 | 0.530 |
Why?
|
| Prognosis | 17 | 2025 | 3872 | 0.520 |
Why?
|
| Endosonography | 1 | 2017 | 100 | 0.520 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2024 | 85 | 0.510 |
Why?
|
| Multivariate Analysis | 12 | 2019 | 996 | 0.500 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 6920 | 0.490 |
Why?
|
| Socioeconomic Factors | 3 | 2024 | 609 | 0.490 |
Why?
|
| Guideline Adherence | 5 | 2023 | 239 | 0.480 |
Why?
|
| Biomedical Research | 1 | 2020 | 405 | 0.480 |
Why?
|
| Elective Surgical Procedures | 3 | 2021 | 155 | 0.470 |
Why?
|
| Reoperation | 5 | 2014 | 653 | 0.470 |
Why?
|
| Chemoradiotherapy | 3 | 2013 | 318 | 0.460 |
Why?
|
| Obesity, Morbid | 3 | 2020 | 243 | 0.460 |
Why?
|
| Precision Medicine | 1 | 2019 | 425 | 0.450 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 1733 | 0.450 |
Why?
|
| Biomarkers, Tumor | 3 | 2025 | 1575 | 0.440 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 443 | 0.430 |
Why?
|
| Esophagoscopy | 1 | 2014 | 90 | 0.430 |
Why?
|
| Lymphatic Metastasis | 7 | 2023 | 498 | 0.430 |
Why?
|
| Pneumonectomy | 4 | 2024 | 214 | 0.420 |
Why?
|
| Hospitalization | 2 | 2023 | 925 | 0.420 |
Why?
|
| Hospital Costs | 1 | 2014 | 114 | 0.410 |
Why?
|
| Research Design | 4 | 2021 | 600 | 0.410 |
Why?
|
| Hospital Mortality | 3 | 2013 | 444 | 0.410 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 32 | 0.410 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 58 | 0.400 |
Why?
|
| Frailty | 2 | 2024 | 86 | 0.400 |
Why?
|
| Gastrectomy | 4 | 2020 | 70 | 0.390 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 787 | 0.390 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 119 | 0.390 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 2369 | 0.380 |
Why?
|
| Veterans | 1 | 2013 | 89 | 0.380 |
Why?
|
| Appendectomy | 2 | 2022 | 36 | 0.370 |
Why?
|
| Odds Ratio | 6 | 2020 | 694 | 0.370 |
Why?
|
| Cohort Studies | 10 | 2022 | 2978 | 0.370 |
Why?
|
| Thoracic Neoplasms | 1 | 2011 | 66 | 0.360 |
Why?
|
| Colonoscopy | 4 | 2021 | 300 | 0.360 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 129 | 0.360 |
Why?
|
| Sigmoid Neoplasms | 1 | 2011 | 9 | 0.350 |
Why?
|
| Diverticulum, Colon | 1 | 2011 | 10 | 0.350 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 1138 | 0.350 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 3054 | 0.340 |
Why?
|
| Organizational Culture | 2 | 2020 | 35 | 0.320 |
Why?
|
| Morbidity | 2 | 2022 | 157 | 0.320 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 409 | 0.320 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2023 | 617 | 0.310 |
Why?
|
| Quality of Life | 1 | 2017 | 1745 | 0.310 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 569 | 0.300 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2016 | 1091 | 0.300 |
Why?
|
| Sentinel Lymph Node | 2 | 2018 | 21 | 0.300 |
Why?
|
| Telemedicine | 2 | 2021 | 213 | 0.280 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2018 | 80 | 0.270 |
Why?
|
| Hospitals, Low-Volume | 2 | 2024 | 20 | 0.270 |
Why?
|
| Confidence Intervals | 4 | 2014 | 219 | 0.250 |
Why?
|
| Body Mass Index | 2 | 2011 | 799 | 0.250 |
Why?
|
| Patient Safety | 2 | 2018 | 220 | 0.250 |
Why?
|
| Focus Groups | 3 | 2021 | 186 | 0.250 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2022 | 67 | 0.240 |
Why?
|
| Postoperative Period | 2 | 2020 | 311 | 0.240 |
Why?
|
| Benchmarking | 3 | 2023 | 80 | 0.240 |
Why?
|
| Outpatients | 2 | 2023 | 106 | 0.240 |
Why?
|
| Gastric Bypass | 2 | 2020 | 112 | 0.240 |
Why?
|
| Fluorouracil | 2 | 2023 | 549 | 0.240 |
Why?
|
| Time Factors | 6 | 2020 | 5429 | 0.240 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1920 | 0.240 |
Why?
|
| Melanoma | 3 | 2018 | 482 | 0.230 |
Why?
|
| Illinois | 3 | 2023 | 502 | 0.230 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 1761 | 0.220 |
Why?
|
| Patient Selection | 3 | 2019 | 690 | 0.220 |
Why?
|
| Drug Therapy | 2 | 2022 | 70 | 0.220 |
Why?
|
| Bariatric Surgery | 2 | 2020 | 204 | 0.210 |
Why?
|
| Analysis of Variance | 4 | 2013 | 899 | 0.210 |
Why?
|
| Prospective Studies | 6 | 2023 | 4471 | 0.210 |
Why?
|
| Decision Support Techniques | 3 | 2014 | 175 | 0.210 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2793 | 0.200 |
Why?
|
| Neoplasm Grading | 3 | 2013 | 390 | 0.200 |
Why?
|
| Thyroidectomy | 1 | 2023 | 171 | 0.200 |
Why?
|
| Young Adult | 7 | 2019 | 6630 | 0.200 |
Why?
|
| Referral and Consultation | 2 | 2018 | 352 | 0.200 |
Why?
|
| Burnout, Professional | 2 | 2021 | 104 | 0.200 |
Why?
|
| Drug Resistance, Microbial | 1 | 2022 | 75 | 0.190 |
Why?
|
| Pancreatic Fistula | 2 | 2019 | 17 | 0.190 |
Why?
|
| Esophagogastric Junction | 2 | 2012 | 34 | 0.190 |
Why?
|
| Surgery Department, Hospital | 2 | 2014 | 43 | 0.190 |
Why?
|
| Thoracotomy | 2 | 2012 | 64 | 0.190 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 555 | 0.190 |
Why?
|
| Comprehension | 1 | 2022 | 82 | 0.190 |
Why?
|
| Machine Learning | 1 | 2024 | 298 | 0.190 |
Why?
|
| CA-125 Antigen | 1 | 2021 | 22 | 0.180 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2021 | 41 | 0.180 |
Why?
|
| Internship and Residency | 3 | 2021 | 1084 | 0.180 |
Why?
|
| Education, Medical, Graduate | 3 | 2021 | 411 | 0.180 |
Why?
|
| Communication Barriers | 1 | 2021 | 31 | 0.180 |
Why?
|
| Office Visits | 1 | 2021 | 49 | 0.180 |
Why?
|
| Incidence | 2 | 2024 | 1661 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 259 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 1774 | 0.170 |
Why?
|
| Checklist | 1 | 2021 | 68 | 0.170 |
Why?
|
| Anticoagulants | 2 | 2022 | 448 | 0.170 |
Why?
|
| Propensity Score | 2 | 2019 | 164 | 0.170 |
Why?
|
| Publishing | 1 | 2021 | 91 | 0.170 |
Why?
|
| Medical Errors | 1 | 2021 | 115 | 0.170 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2020 | 22 | 0.170 |
Why?
|
| Equipment Design | 1 | 2021 | 420 | 0.160 |
Why?
|
| Survival Analysis | 6 | 2020 | 1511 | 0.160 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 44 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2020 | 42 | 0.160 |
Why?
|
| Embolization, Therapeutic | 1 | 2022 | 265 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2021 | 325 | 0.160 |
Why?
|
| Health Policy | 2 | 2019 | 190 | 0.160 |
Why?
|
| Patient Preference | 1 | 2020 | 120 | 0.160 |
Why?
|
| Patient Education as Topic | 1 | 2022 | 369 | 0.160 |
Why?
|
| Reference Standards | 1 | 2019 | 143 | 0.150 |
Why?
|
| Gastroparesis | 1 | 2019 | 14 | 0.150 |
Why?
|
| Health Status Indicators | 1 | 2019 | 103 | 0.150 |
Why?
|
| Colon | 1 | 2022 | 527 | 0.150 |
Why?
|
| Fundoplication | 1 | 2019 | 71 | 0.150 |
Why?
|
| Physicians, Women | 1 | 2019 | 59 | 0.150 |
Why?
|
| Treatment Failure | 1 | 2019 | 288 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 399 | 0.150 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2019 | 81 | 0.150 |
Why?
|
| SEER Program | 1 | 2019 | 229 | 0.150 |
Why?
|
| Needs Assessment | 1 | 2019 | 159 | 0.140 |
Why?
|
| Health Personnel | 1 | 2020 | 224 | 0.140 |
Why?
|
| Career Choice | 1 | 2019 | 153 | 0.140 |
Why?
|
| Algorithms | 2 | 2018 | 1960 | 0.140 |
Why?
|
| Communication | 1 | 2021 | 462 | 0.140 |
Why?
|
| Health Status | 1 | 2019 | 375 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 808 | 0.130 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1179 | 0.130 |
Why?
|
| Accreditation | 2 | 2014 | 62 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 121 | 0.130 |
Why?
|
| Learning | 1 | 2019 | 295 | 0.130 |
Why?
|
| Stents | 1 | 2019 | 417 | 0.130 |
Why?
|
| Physical Examination | 1 | 2017 | 151 | 0.130 |
Why?
|
| Adolescent | 6 | 2019 | 9495 | 0.120 |
Why?
|
| Endoscopy | 1 | 2019 | 359 | 0.120 |
Why?
|
| Neuroendocrine Tumors | 2 | 2007 | 132 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 505 | 0.120 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2013 | 153 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 657 | 0.110 |
Why?
|
| Health Care Surveys | 2 | 2018 | 286 | 0.110 |
Why?
|
| Curriculum | 1 | 2018 | 583 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2685 | 0.110 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 2729 | 0.100 |
Why?
|
| Tissue Expansion Devices | 1 | 2013 | 8 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 630 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 864 | 0.100 |
Why?
|
| Malpractice | 1 | 2013 | 56 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 488 | 0.100 |
Why?
|
| Decision Making | 1 | 2018 | 680 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2009 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2018 | 807 | 0.100 |
Why?
|
| Breast Implants | 1 | 2013 | 27 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2014 | 96 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2014 | 108 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 248 | 0.100 |
Why?
|
| Pancreatic Diseases | 1 | 2013 | 56 | 0.100 |
Why?
|
| Pandemics | 3 | 2024 | 808 | 0.100 |
Why?
|
| American Cancer Society | 1 | 2012 | 13 | 0.100 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 118 | 0.100 |
Why?
|
| Professional Practice | 1 | 2012 | 45 | 0.100 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 33 | 0.090 |
Why?
|
| Calibration | 1 | 2012 | 103 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2013 | 594 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 3514 | 0.090 |
Why?
|
| Observation | 1 | 2011 | 38 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 120 | 0.090 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2011 | 23 | 0.090 |
Why?
|
| Operative Time | 2 | 2024 | 156 | 0.090 |
Why?
|
| Physicians | 1 | 2018 | 693 | 0.090 |
Why?
|
| Gastroplasty | 1 | 2011 | 26 | 0.090 |
Why?
|
| Pancreas | 1 | 2013 | 252 | 0.090 |
Why?
|
| Mammaplasty | 1 | 2013 | 119 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2012 | 315 | 0.090 |
Why?
|
| Forecasting | 1 | 2012 | 311 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2011 | 63 | 0.090 |
Why?
|
| Sigmoidoscopy | 1 | 2011 | 38 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2012 | 186 | 0.090 |
Why?
|
| Age Factors | 4 | 2020 | 1903 | 0.090 |
Why?
|
| Abdominal Pain | 1 | 2011 | 144 | 0.080 |
Why?
|
| Piperazines | 1 | 2011 | 288 | 0.080 |
Why?
|
| Job Satisfaction | 2 | 2019 | 80 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 313 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 379 | 0.070 |
Why?
|
| Hospitals, Veterans | 1 | 2007 | 22 | 0.070 |
Why?
|
| Hospitals, Community | 2 | 2023 | 33 | 0.070 |
Why?
|
| Principal Component Analysis | 2 | 2019 | 164 | 0.060 |
Why?
|
| Florida | 1 | 2023 | 60 | 0.050 |
Why?
|
| California | 1 | 2023 | 156 | 0.050 |
Why?
|
| Yttrium Radioisotopes | 1 | 2022 | 46 | 0.050 |
Why?
|
| Rural Population | 1 | 2022 | 151 | 0.050 |
Why?
|
| Obesity | 1 | 2008 | 1014 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2013 | 304 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 85 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 307 | 0.040 |
Why?
|
| Sexual Harassment | 1 | 2019 | 9 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 271 | 0.040 |
Why?
|
| Intraabdominal Infections | 1 | 2019 | 10 | 0.040 |
Why?
|
| Gastric Emptying | 1 | 2019 | 25 | 0.040 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2019 | 31 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2019 | 38 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 242 | 0.040 |
Why?
|
| ROC Curve | 2 | 2013 | 786 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2018 | 20 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 45 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2020 | 161 | 0.040 |
Why?
|
| Reimbursement, Incentive | 1 | 2018 | 38 | 0.040 |
Why?
|
| Ownership | 1 | 2018 | 27 | 0.040 |
Why?
|
| Axilla | 1 | 2018 | 104 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1052 | 0.040 |
Why?
|
| Smoking | 1 | 2021 | 640 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 306 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 375 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 307 | 0.030 |
Why?
|
| Carcinoma | 1 | 2020 | 438 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2020 | 479 | 0.030 |
Why?
|
| Observer Variation | 1 | 2018 | 612 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 290 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 98 | 0.030 |
Why?
|
| Relative Value Scales | 1 | 2014 | 10 | 0.030 |
Why?
|
| Lawyers | 1 | 2013 | 2 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 98 | 0.030 |
Why?
|
| Ulcer | 1 | 2013 | 38 | 0.030 |
Why?
|
| Breast Implantation | 1 | 2013 | 14 | 0.030 |
Why?
|
| Mitosis | 1 | 2013 | 156 | 0.030 |
Why?
|
| Medicine | 1 | 2013 | 95 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 359 | 0.020 |
Why?
|
| Medical Records | 1 | 2013 | 122 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2013 | 172 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 127 | 0.020 |
Why?
|
| Child | 1 | 2022 | 7309 | 0.020 |
Why?
|
| Mastectomy | 1 | 2013 | 257 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 871 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 239 | 0.020 |
Why?
|
| Sepsis | 1 | 2014 | 351 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 239 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 986 | 0.020 |
Why?
|
| Disease Management | 1 | 2011 | 341 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 1072 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1771 | 0.020 |
Why?
|
| Laparotomy | 1 | 2008 | 68 | 0.020 |
Why?
|
| Adenoma, Islet Cell | 1 | 2007 | 28 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 305 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 94 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2011 | 596 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1607 | 0.010 |
Why?
|